ClinicalTrials.gg
TerminatedNCT01203930Updated Nov 16, 2018Results posted

A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

A Phase 2 interventional study of Idelalisib and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by Gilead Sciences. Terminated at 6 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
12th of 25
105 · median 102
Started
2010
with 1 other
Phase 2
11 of 25
none open now
Registered
3rd of 25
by date
Lead sponsor
19 of 25
Gilead Sciences

Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 12th largest by enrollment, is one of 2 that started in 2010, is one of 11 in phase 2, and was the 3rd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About idelalisib

idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This study is to evaluate the safety and clinical activity of idelalisib alone and in combination with rituximab in patients with CLL or SLL.

This Phase 2 study will be the first time that idelalisib is administered to previously untreated patients with hematologic malignancies. Idelalisib has demonstrated clinical activity as a single agent in relapsed or refractory CLL and SLL with acceptable toxicity, which supports its evaluation in previously untreated patients. The study population is limited to patients over 65 years of age because younger patients are generally appropriate for standard immunochemotherapy regimens that are highly active. Since the mechanism of action of idelalisib is distinct from rituximab, it is hypothesized that the combination will be more active than either agent alone. This study will establish initial safety and clinical activity of idelalisib in combination with rituximab in patients with CLL or SLL. Cohort 2 of this study will establish safety and clinical activity of idelalisib alone in subjects with untreated CLL or SLL.

03

Conditions studied

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)

Keywords

  • CLL
  • SLL
  • GS-1101
  • CAL-101
  • Phosphatidylinositol 3-kinase (PI3K)
  • Rituximab
  • Rituxan
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • or cytologically confirmed CLL or SLL.
  • Age ≥ 65
  • Presence of measurable lymphadenopathy (defined as the presence of ≥1 nodal lesion that measures ≥ 1.5 cm in the longest diameter (LD) and ≥ 1.0 cm in the longest perpendicular diameter (LPD) as assessed by physical exam, computed tomography (CT) or magnetic resonance imaging (MRI)).
  • CLL - Binet Stage C or Rai Stage III or IV or has active disease defined by meeting at least one of the following criteria:

    • Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia and/or thrombocytopenia
    • Massive (ie, > 6 cm below the left costal margin) or progressive or symptomatic splenomegaly
    • Massive nodes (ie, > 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy
    • Progressive lymphocytosis with an increase of more than 50% over a 2-month period or lymphocyte doubling time of less than 6 months
    • anemia and/or thrombocytopenia poorly responsive to or other standard therapy
    • At least one of the following disease-related symptoms:

      • Unintentional weight loss ≥ 10% within the previous 6 months
      • Significant fatigue
      • Fevers > 100.4 F for ≥ 2 weeks without other evidence of infection
      • Night sweats for ≥ 1 month without evidence of infection
  • SLL - has active disease as defined above for CLL, except the lymphocytosis criterion does not apply
  • World Health Organization (WHO) Performance Status of ≤ 2
  • For men of , willing to use adequate methods of for the entire duration of the study
  • Able to provide written

Key Exclusion Criteria:

  • Prior therapy for CLL or SLL, except corticosteroids for symptom relief
  • Treatment with a short course of corticosteroids for symptom relief within 1-week prior to Visit 1
  • Known active central nervous system involvement of the
  • Ongoing active, serious infection requiring systemic therapy. Patients may be receiving prophylactic antibiotics and antiviral therapy at the discretion of the treating physician.
  • Serum creatinine ≥ 2.0 mg/dL
  • Serum ≥ 2 mg/dL (unless due to Gilbert's syndrome) or serum transaminases (ie, (AST), alanine aminotransferase (ALT)) ≥ 2 x
  • Positive test for (HIV) antibodies
  • Active or C (confirmed by ribonucleic acid (RNA) test). Patients with serologic evidence of prior exposure are eligible.
  • History of a non-CLL malignancy except for the following: adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for ≥ 1 year prior to study entry, other adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for ≥ 5 years.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Idelalisib

    This arm consists of 2 cohorts. Participants in Cohort 1 will receive idelalisib for up to twelve 28-day cycles (or development of unacceptable toxicity) plus rituximab (8 doses through the end of Cycle 2). Upon completion of twelve 28-cycles, participants are eligible to remain on idelalisib in a continuation protocol. Participants in Cohort 2 will receive idelalisib until disease progression or development of unacceptable toxicity.

    Drug: Idelalisib · Drug: Rituximab

Interventions

  • Idelalisib 150 mg tablets administered orally twice daily

    Also known as: Zydelig®, GS-1101, CAL-101

  • Rituximab 375 mg/m\^2 administered intravenously once weekly x 8 weeks

    Also known as: Rituxan

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR was assessed based on standardized International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria as specifically modified for this study to reflect current recommendations which consider the mechanism of action of idelalisib and similar drugs, and was defined as the proportion of participants achieving a complete response (CR) or partial response (PR) as assessed by the investigator. Based on the CLL response definition in the protocol (modified Hallek 2008), the parameters of lymphadenopathy, liver and/or spleen size, constitutional symptoms, polymorphonuclear leukocytes, circulating clonal B-lymphocytes, platelet count, hemoglobin, and marrow were assessed. * CR: meeting all defined criteria * PR: meeting at least 2 of the criteria of circulating lymphocytes, lymphadenopathy, liver, spleen, or bone marrow (or only lymphadenopathy if liver and spleen normal at baseline) and at least 1 of the criteria for polymorphonuclear leukocytes, platelet count, or hemoglobin.

    Time frame: Up to 28 Months

Secondary outcomes

  1. Overall Safety of Idelalisib

    The overall safety of idelalisib was assessed as the percentage of participants experiencing treatment-emergent adverse events (AEs; Serious AEs, Grade ≥ 3 AEs, AEs related to idelalisib, and AEs leading to discontinuation of idelalisib).

    Time frame: Up to 28 Months

  2. Lymphadenopathy Response Rate

    Lymphadenopathy response rate was defined as the percentage of participants with a ≥ 50% reduction from baseline in the sum of the perpendicular diameters of all measurable lesions while receiving study therapy.

    Time frame: Baseline and up to 28 Months

  3. Percent Change From Baseline in the Sum of the Product of the Greatest Perpendicular Diameters (SPD) of All Measurable Lesions

    Time frame: Baseline; Weeks 8, 16, 24, 36, 48, 60, 72, 84, 96, 108, and 120

  4. Duration of Response

    Duration of response (DOR) was defined as the interval from the first documentation of CR or PR to the earlier of the first documentation of disease progression or death from any cause.

    Time frame: Up to 28 Months

  5. Progression-Free Survival

    Progression-free survival (PFS) was defined as the interval from the first dose date of drug to the earlier of the first documentation of definitive disease progression or death from any cause. Progression was defined using the Standardized IWCLL criteria as specifically modified for this study to consider the mechanism of action of idelalisib and similar drugs. The occurrence of any of the following events indicated progression: 1. Evidence of any new disease 2. Evidence of worsening of index lesions, spleen or liver, or non-index disease 3. Decrease in platelet count or hemoglobin that is attributable to CLL and is confirmed by bone marrow biopsy

    Time frame: Up to 28 Months

  6. Idelalisib Plasma Concentrations (Cohort 1)

    Time frame: Predose and 1.5 hours postdose at Weeks 0, 4, and 24

  7. Idelalisib Plasma Concentrations (Cohort 2)

    Time frame: Predose and 1.5 hours postdose at Weeks 0 and 4 and predose at Weeks 8 and 20

  8. Changes in Potential Pharmacodynamic Markers of Drug Activity in Plasma and Whole Blood

    Changes in potential pharmacodynamic markers of drug activity will include assessments of chemokine and cytokine concentrations, effects on the activity of PI3K and related pathways, and effect on cell migration and other functional outcomes. This endpoint will be assessed at the following time points: * Idelalisib+Rituximab (Cohort 1): Predose and 1.5 hour postdose on Day 1 and predose on Days 15, 29, 57, 113, and 169 * Idelalisib (Cohort 2): Predose on Days 1, 29, 57, 141

    Time frame: Up to 169 days

  9. Overall Survival

    Overall survival (OS) is defined as the interval from the start of study treatment to death from any cause.

    Time frame: Up to 28 Months

07

Results

Posted May 22, 2017

Participant flow

Participants were enrolled at study sites in the United States. The first participant was screened on 28 September 2010. The last study visit occurred on 07 June 2016.

Participant flow — Overall Study
MilestoneIdelalisib+Rituximab (Cohort 1)Idelalisib (Cohort 2)
Started6441
Completed430
Not completed2141
Withdrew: Disease progression04
Withdrew: Death31
Withdrew: Withdrew consent110
Withdrew: Investigator request08
Withdrew: Study terminated by sponsor012
Withdrew: Poor tolerance of study drug01
Withdrew: Adverse event175

Outcome measures

PrimaryOverall Response Rate (ORR)

ORR was assessed based on standardized International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria as specifically modified for this study to reflect current recommendations which consider the mechanism of action of idelalisib and similar drugs, and was defined as the proportion of participants achieving a complete response (CR) or partial response (PR) as assessed by the investigator. Based on the CLL response definition in the protocol (modified Hallek 2008), the parameters of lymphadenopathy, liver and/or spleen size, constitutional symptoms, polymorphonuclear leukocytes, circulating clonal B-lymphocytes, platelet count, hemoglobin, and marrow were assessed. * CR: meeting all defined criteria * PR: meeting at least 2 of the criteria of circulating lymphocytes, lymphadenopathy, liver, spleen, or bone marrow (or only lymphadenopathy if liver and spleen normal at baseline) and at least 1 of the criteria for polymorphonuclear leukocytes, platelet count, or hemoglobin.

Time frame:
Up to 28 Months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsIdelalisib+Rituximab (Cohort 1)Idelalisib (Cohort 2)
Overall Response Rate (ORR)96.9 (89.2 to 99.6)87.8 (73.8 to 95.9)
SecondaryOverall Safety of Idelalisib

The overall safety of idelalisib was assessed as the percentage of participants experiencing treatment-emergent adverse events (AEs; Serious AEs, Grade ≥ 3 AEs, AEs related to idelalisib, and AEs leading to discontinuation of idelalisib).

Time frame:
Up to 28 Months
Reported as:
Number · percentage of participants
Overall Safety of Idelalisib
percentage of participantsIdelalisib+Rituximab (Cohort 1)Idelalisib (Cohort 2)
Any AE100.0100.0
Serious AE48.468.3
Grade ≥ 3 AE76.685.4
AE related to idelalisib81.397.6
AE leading to permanent drug discontinuation28.156.1
SecondaryLymphadenopathy Response Rate

Lymphadenopathy response rate was defined as the percentage of participants with a ≥ 50% reduction from baseline in the sum of the perpendicular diameters of all measurable lesions while receiving study therapy.

Time frame:
Baseline and up to 28 Months
Reported as:
Number · percentage of participants
Lymphadenopathy Response Rate
percentage of participantsIdelalisib+Rituximab (Cohort 1)Idelalisib (Cohort 2)
Lymphadenopathy Response Rate98.0 (89.4 to 99.9)86.8 (71.9 to 95.6)
SecondaryPercent Change From Baseline in the Sum of the Product of the Greatest Perpendicular Diameters (SPD) of All Measurable Lesions
Time frame:
Baseline; Weeks 8, 16, 24, 36, 48, 60, 72, 84, 96, 108, and 120
Reported as:
Median · percent change
Percent Change From Baseline in the Sum of the Product of the Greatest Perpendicular Diameters (SPD) of All Measurable Lesions
percent changeIdelalisib+Rituximab (Cohort 1)Idelalisib (Cohort 2)
% Change at Wk 8-100.0 (-100.0 to -8.3)-69.8 (-100.0 to 0.0)
% Change at Wk 16-100.0 (-100.0 to -69.2)-74.5 (-100.0 to 0.0)
% Change at Wk 24-100.0 (-100.0 to -50.0)-76.0 (-100.0 to 0.0)
% Change at Wk 36-100.0 (-100.0 to -66.7)-77.5 (-100.0 to 0.0)
% Change at Wk 48-100.0 (-100.0 to -50.0)-73.9 (-98.3 to 44.4)
% Change at Wk 60—-69.7 (-93.3 to -56.7)
% Change at Wk 72—-78.0 (-85.5 to -68.8)
% Change at Wk 84—-80.0 (-91.2 to -68.1)
% Change at Wk 96—-81.3 (-100.0 to -62.5)
% Change at Wk 108—-78.1 (-78.1 to -78.1)
% Change at Wk 120—-71.9 (-71.9 to -71.9)
Best % Change-100.0 (-100.0 to -40.0)-81.1 (-100.0 to 0.0)
SecondaryDuration of Response

Duration of response (DOR) was defined as the interval from the first documentation of CR or PR to the earlier of the first documentation of disease progression or death from any cause.

Time frame:
Up to 28 Months
Reported as:
Median · months
Duration of Response
monthsIdelalisib+Rituximab (Cohort 1)Idelalisib (Cohort 2)
Duration of ResponseNA (NA to NA)14.8 (10.0 to NA)
SecondaryProgression-Free Survival

Progression-free survival (PFS) was defined as the interval from the first dose date of drug to the earlier of the first documentation of definitive disease progression or death from any cause. Progression was defined using the Standardized IWCLL criteria as specifically modified for this study to consider the mechanism of action of idelalisib and similar drugs. The occurrence of any of the following events indicated progression: 1. Evidence of any new disease 2. Evidence of worsening of index lesions, spleen or liver, or non-index disease 3. Decrease in platelet count or hemoglobin that is attributable to CLL and is confirmed by bone marrow biopsy

Time frame:
Up to 28 Months
Reported as:
Median · months
Progression-Free Survival
monthsIdelalisib+Rituximab (Cohort 1)Idelalisib (Cohort 2)
Progression-Free SurvivalNA (NA to NA)26.2 (14.0 to NA)
SecondaryIdelalisib Plasma Concentrations (Cohort 1)
Time frame:
Predose and 1.5 hours postdose at Weeks 0, 4, and 24
Reported as:
Median · ng/mL
Idelalisib Plasma Concentrations (Cohort 1)
ng/mLIdelalisib+Rituximab (Cohort 1)
Week 0 predose0.0 (0.0 to 0.0)
Week 0 postdose1710.0 (1060.0 to 2660.0)
Week 4 predose305.0 (189.0 to 606.0)
Week 4 postdose1720.0 (1090.0 to 2500.0)
Week 24 predose256.5 (173.5 to 625.5)
Week 24 postdose1460.0 (925.0 to 2010.0)
SecondaryIdelalisib Plasma Concentrations (Cohort 2)
Time frame:
Predose and 1.5 hours postdose at Weeks 0 and 4 and predose at Weeks 8 and 20
Reported as:
Median · ng/mL
Idelalisib Plasma Concentrations (Cohort 2)
ng/mLIdelalisib (Cohort 2)
Week 0 predose0.0 (0.0 to 0.0)
Week 0 postdose2190.0 (1575.0 to 2920.0)
Week 4 predose293.0 (228.0 to 549.0)
Week 4 postdose2120.0 (1850.0 to 2590.0)
Week 8 predose453.0 (207.0 to 904.0)
Week 20 predose590.0 (317.0 to 971.5)
SecondaryChanges in Potential Pharmacodynamic Markers of Drug Activity in Plasma and Whole Blood

Changes in potential pharmacodynamic markers of drug activity will include assessments of chemokine and cytokine concentrations, effects on the activity of PI3K and related pathways, and effect on cell migration and other functional outcomes. This endpoint will be assessed at the following time points: * Idelalisib+Rituximab (Cohort 1): Predose and 1.5 hour postdose on Day 1 and predose on Days 15, 29, 57, 113, and 169 * Idelalisib (Cohort 2): Predose on Days 1, 29, 57, 141

Time frame:
Up to 169 days

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival (OS) is defined as the interval from the start of study treatment to death from any cause.

Time frame:
Up to 28 Months

No measurements were reported for this outcome.

Adverse events

Collected over Up to 28 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Idelalisib+Rituximab (Cohort 1)—31/64 (48.4%)63/64 (98.4%)
Idelalisib (Cohort 2)—28/41 (68.3%)40/41 (97.6%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventIdelalisib+Rituximab (Cohort 1)Idelalisib (Cohort 2)
DiarrhoeaGastrointestinal disorders6/647/41
PneumoniaInfections and infestations8/645/41
ColitisGastrointestinal disorders6/644/41
PyrexiaGeneral disorders2/643/41
Febrile neutropeniaBlood and lymphatic system disorders2/642/41
CellulitisInfections and infestations1/642/41
DehydrationMetabolism and nutrition disorders1/642/41
CoughRespiratory, thoracic and mediastinal disorders0/642/41
PneumonitisRespiratory, thoracic and mediastinal disorders2/642/41
DyspnoeaRespiratory, thoracic and mediastinal disorders2/641/41
Most frequent other events
Showing 10 of 68
Most frequent other events
EventIdelalisib+Rituximab (Cohort 1)Idelalisib (Cohort 2)
DiarrhoeaGastrointestinal disorders31/6427/41
PyrexiaGeneral disorders26/6413/41
NauseaGastrointestinal disorders24/6414/41
RashSkin and subcutaneous tissue disorders24/6414/41
ChillsGeneral disorders23/646/41
CoughRespiratory, thoracic and mediastinal disorders21/6411/41
FatigueGeneral disorders20/6413/41
ConstipationGastrointestinal disorders11/6412/41
Alanine aminotransferase increasedInvestigations18/6411/41
Upper respiratory tract infectionInfections and infestations7/6411/41

Baseline characteristics

Intent-to-treat (ITT) Analysis Set: participants who received at least 1 dose of idelalisib.

Age, Customized
Age, Customized(participants)Idelalisib+Rituximab (Cohort 1)Idelalisib (Cohort 2)Total
< 70 Years291443
≥ 70 Years352762
Sex: Female, Male
Sex: Female, Male(Participants)Idelalisib+Rituximab (Cohort 1)Idelalisib (Cohort 2)Total
Female24933
Male403272
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Idelalisib+Rituximab (Cohort 1)Idelalisib (Cohort 2)Total
Hispanic or Latino011
Not Hispanic or Latino6440104
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Idelalisib+Rituximab (Cohort 1)Idelalisib (Cohort 2)Total
White/Caucasian6140101
Black or African American112
Asian101
Other101
08

Study locations

6 sites
  • University of California, San Diego, Moores Cancer Center
    La Jolla, California 92093-0820, United States
  • Stanford University School of Medicine
    Stanford, California 94304, United States
  • Columbia University - Herbert Irving Pavilion
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • The Universtity of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Publications

  • O'Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood. 2015 Dec 17;126(25):2686-94. doi: 10.1182/blood-2015-03-630947. Epub 2015 Oct 15. PubMed 26472751 ↗

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2010 to primary completion in Aug 2015, 58 months.

Results were first posted in May 2017, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2010
First posted
Sep 17, 2010
StartActual
Oct 2010
Primary completionActual
Aug 2015
CompletionActual
Jun 2016
Results first posted
May 22, 2017
Last update
Nov 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01203930
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Sep 17, 2010
Start date
Oct 2010
Primary completion
Aug 2015
Completion
Jun 2016
Results posted
May 22, 2017
Last update
Nov 16, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idelalisib

Start the discussion